BioPharma Dive·3 min read·medium
Lilly climbs, Novo falls as obesity drug battle intensifies
K
Kristin Jensen
✦AI Summary
Eli Lilly's stock rose as its injectable obesity drugs outperformed expectations, while Novo Nordisk faced a decline following a trial setback and lower-than-expected sales for its Wegovy pill. Both companies are competing aggressively in the high-growth GLP-1 drug market.
A research disappointment and a miss on Wegovy pill sales hurt Novo, while Lilly’s injectable franchise once again surpassed analyst expectations.
businesshealtheconomy
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in